Medicines management programme: preferred medicines: angiotensin-II receptor blockers

Hdl Handle:
http://hdl.handle.net/10147/325085
Title:
Medicines management programme: preferred medicines: angiotensin-II receptor blockers
Authors:
Barry, Michael
Affiliation:
Health Serivce Executive
Citation:
Barry M. Medicines management programme: preferred medicines: angiotensin-II receptor blockers. Dublin: Health Service Executive; 2013. 19p.
Publisher:
Health Service Excutive (HSE)
Issue Date:
Sep-2013
URI:
http://hdl.handle.net/10147/325085
Additional Links:
http://www.hse.ie/yourmedicines
Item Type:
Report
Language:
en
Description:
There are eight licensed angiotensin‐II receptor blockers (ARBs) available in Ireland. Annual expenditure on ARBs under the General Medical Services (GMS) scheme is approximately €25 million. The selection of a preferred ARB under the Medicines Management Programme (MMP) is designed to support prescribers in choosing a medicine of proven safety and efficacy in the management of patients with cardiovascular conditions, in particular hypertension and heart failure. GMS data suggest that ARBs may not be optimally prescribed nationally. In selecting a preferred ARB the MMP aims to enhance the quality of prescribing and provide value for money. The guidance may not be applicable to all patient populations, e.g. children and patients with congenital cardiac conditions, in which circumstances specialist advice should be sought. The use of ARBs is not recommended during the first trimester of pregnancy. The use of ARBs is contraindicated during the second and third trimesters of pregnancy.
Keywords:
MEDICINES; DRUG; REGULATION

Full metadata record

DC FieldValue Language
dc.contributor.authorBarry, Michaelen_GB
dc.date.accessioned2014-08-22T10:49:20Z-
dc.date.available2014-08-22T10:49:20Z-
dc.date.issued2013-09-
dc.identifier.citationBarry M. Medicines management programme: preferred medicines: angiotensin-II receptor blockers. Dublin: Health Service Executive; 2013. 19p.en_GB
dc.identifier.urihttp://hdl.handle.net/10147/325085-
dc.descriptionThere are eight licensed angiotensin‐II receptor blockers (ARBs) available in Ireland. Annual expenditure on ARBs under the General Medical Services (GMS) scheme is approximately €25 million. The selection of a preferred ARB under the Medicines Management Programme (MMP) is designed to support prescribers in choosing a medicine of proven safety and efficacy in the management of patients with cardiovascular conditions, in particular hypertension and heart failure. GMS data suggest that ARBs may not be optimally prescribed nationally. In selecting a preferred ARB the MMP aims to enhance the quality of prescribing and provide value for money. The guidance may not be applicable to all patient populations, e.g. children and patients with congenital cardiac conditions, in which circumstances specialist advice should be sought. The use of ARBs is not recommended during the first trimester of pregnancy. The use of ARBs is contraindicated during the second and third trimesters of pregnancy.en_GB
dc.language.isoenen
dc.publisherHealth Service Excutive (HSE)en_GB
dc.relation.urlhttp://www.hse.ie/yourmedicinesen_GB
dc.subjectMEDICINESen_GB
dc.subjectDRUGen_GB
dc.subjectREGULATIONen_GB
dc.titleMedicines management programme: preferred medicines: angiotensin-II receptor blockersen_GB
dc.typeReporten
dc.contributor.departmentHealth Serivce Executiveen_GB
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.